Petros Pharmaceuticals (PTPI) Competitors $0.03 0.00 (0.00%) As of 03:41 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTPI vs. SNGX, VAXX, PLRZ, NBY, CANF, CERO, INM, SXTP, REVB, and LIPOShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Soligenix (SNGX), Vaxxinity (VAXX), Polyrizon (PLRZ), NovaBay Pharmaceuticals (NBY), Can-Fite BioPharma (CANF), CERo Therapeutics (CERO), InMed Pharmaceuticals (INM), 60 Degrees Pharmaceuticals (SXTP), Revelation Biosciences (REVB), and Lipella Pharmaceuticals (LIPO). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Its Competitors Soligenix Vaxxinity Polyrizon NovaBay Pharmaceuticals Can-Fite BioPharma CERo Therapeutics InMed Pharmaceuticals 60 Degrees Pharmaceuticals Revelation Biosciences Lipella Pharmaceuticals Petros Pharmaceuticals (NASDAQ:PTPI) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends. Does the media refer more to PTPI or SNGX? In the previous week, Soligenix had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 1 mentions for Soligenix and 0 mentions for Petros Pharmaceuticals. Soligenix's average media sentiment score of 0.29 beat Petros Pharmaceuticals' score of 0.00 indicating that Soligenix is being referred to more favorably in the news media. Company Overall Sentiment Petros Pharmaceuticals Neutral Soligenix Neutral Do insiders and institutionals believe in PTPI or SNGX? 12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is PTPI or SNGX more profitable? Petros Pharmaceuticals' return on equity of -78.22% beat Soligenix's return on equity.Company Net Margins Return on Equity Return on Assets Petros PharmaceuticalsN/A -78.22% -23.50% Soligenix N/A -223.89%-103.50% Which has stronger valuation and earnings, PTPI or SNGX? Petros Pharmaceuticals has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPetros Pharmaceuticals$5.11M0.18-$8.16M-$60.870.00Soligenix$120K36.95-$8.27M-$4.29-0.32 Do analysts rate PTPI or SNGX? Soligenix has a consensus target price of $6.00, suggesting a potential upside of 341.18%. Given Soligenix's stronger consensus rating and higher probable upside, analysts clearly believe Soligenix is more favorable than Petros Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Soligenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, PTPI or SNGX? Petros Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. SummarySoligenix beats Petros Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$897K$815.77M$5.52B$9.41BDividend YieldN/A4.84%3.80%4.04%P/E Ratio-0.011.4128.0419.84Price / Sales0.1825.49429.5399.59Price / CashN/A19.5635.8457.94Price / Book0.016.878.125.65Net Income-$8.16M-$4.17M$3.25B$258.00M7 Day PerformanceN/A0.03%0.97%2.09%1 Month PerformanceN/A2.12%7.36%11.13%1 Year PerformanceN/A2.14%31.31%18.40% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros PharmaceuticalsN/A$0.03flatN/A-99.7%$897K$5.11M-0.0120Gap UpSNGXSoligenix2.5958 of 5 stars$1.12-6.7%N/A-80.1%$3.92M-$117.03K-0.2620Analyst ForecastVAXXVaxxinityN/A$0.05+66.7%N/A-100.0%$3.80MN/A-0.1190PLRZPolyrizonN/A$0.70-1.2%N/AN/A$3.75MN/A0.00N/ANBYNovaBay Pharmaceuticals1.6021 of 5 stars$0.66+5.4%$0.85+28.2%-68.6%$3.66M$9.78M-0.0130Gap UpCANFCan-Fite BioPharma2.411 of 5 stars$1.02flat$14.00+1,272.5%-71.3%$3.61M$674K-0.578CEROCERo Therapeutics3.9213 of 5 stars$8.92-3.7%$45.00+404.5%-97.9%$3.58MN/A0.008INMInMed Pharmaceuticals0.456 of 5 stars$2.73-6.2%N/A-51.3%$3.51M$4.60M-0.2310Gap DownSXTP60 Degrees Pharmaceuticals2.7385 of 5 stars$2.33-2.1%$7.00+200.4%+29.1%$3.51M$665.45K-0.053REVBRevelation Biosciences0.9566 of 5 stars$2.58+13.1%N/A-96.8%$3.50MN/A-0.0310High Trading VolumeLIPOLipella Pharmaceuticals1.6549 of 5 stars$0.85+9.1%N/A-79.4%$3.49M$536.36K-0.214 Related Companies and Tools Related Companies Soligenix Competitors Vaxxinity Competitors Polyrizon Competitors NovaBay Pharmaceuticals Competitors Can-Fite BioPharma Competitors CERo Therapeutics Competitors InMed Pharmaceuticals Competitors 60 Degrees Pharmaceuticals Competitors Revelation Biosciences Competitors Lipella Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTPI) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTPI Stock Alerts